Quest Diagnostics stock climbs on a $3.12 EPS beat
Published on 08/28/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics Incorporated (US74834L1008) stock climbed after the company's July 23, 2026 quarter showed $3.12 in EPS and $3.04 billion in revenue, both above Wall Street estimates. The same quarter also marked a 10.2% increase in revenue year over year, giving investors a clear earnings-day reference point.
The current share context is also firm: Quest Diagnostics last changed hands at $247.69 on August 28, 2026, up $2.30, or 0.94%, with a market capitalization of $27.04 billion. The stock has also gained 38.22% over the past 12 months, while a market portal put the average target price at $235.31.
July 23 sets the tone
The July 23, 2026 report supplied the most relevant operating numbers for the current setup. Revenue of $3.04 billion topped the $2.97 billion consensus, while EPS of $3.12 beat the $2.82 estimate by $0.30.
That same report showed a 10.2% year-over-year revenue increase and FY 2026 guidance of $11.05 to $11.25 in EPS. On the Street, the current average estimate sits at $11.15 for the fiscal year, placing the company's own range slightly above the midpoint of consensus.
Valuation stays busy
The stock's 12-month gain of 38.22% stands out next to a consensus target of $235.31 and a last price of $247.69 on August 28, 2026. That combination leaves the shares trading above the average target, even after the latest earnings beat.
Quest Diagnostics also carried a return on equity of 16.01% and a net margin of 9.18% in the latest quarter cited by market coverage. For investors, those two figures matter because they frame how much of the revenue base is turning into profit while the top line keeps growing.
Diagnostics at scale
Quest Diagnostics is still a business built around laboratory testing and diagnostic services, with volume and reimbursement trends driving much of the earnings picture. The July 23 quarter showed that the model can still convert higher revenue into stronger EPS, even as guidance remains the key monitor.
Price at the close
Quest Diagnostics stock traded at $247.69 on August 28, 2026, with a market cap of $27.04 billion. The stock's 52-week range was 120.87 to 159.36 in the latest quote snapshot.
Company
Company: Quest Diagnostics Incorporated
ISIN: US74834L1008
Ticker: DGX
Exchange: NYSE
Price (as of August 28, 2026): $247.69 USD
Market cap: $27.04 billion
Sector / Industry: Health Care / Diagnostics & Research
Index membership: S&P 500
More on Quest Diagnostics stock
Quest Diagnostics stock is tied to a simple driver: test volumes, pricing, and margins in a large U.S. diagnostics franchise.
